Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund experienced a decline of 1.73% on November 17, with a trading volume of 84.4024 million yuan, indicating a potential volatility in the innovative drug sector [1] Group 1: Fund Performance - The fund's latest share count increased by 3 million shares, bringing the total to 1.586 billion shares, with a significant increase of 672 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated at 1.437 billion yuan [1] - Since its inception on September 12, 2025, the fund has reported a return of -9.41%, while the return over the past month is 1.13% [1] Group 2: Management and Benchmark - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan overseeing its operations [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1]
11月17日港股通创新药ETF南方（159297）份额增加300.00万份
Xin Lang Cai Jing·2025-11-18 01:09